Early therapy following myocardial infarction: Arguments for and against implantable cardioverter-defibrillators

Future Cardiology

Volumn 6, Issue 3, 2010, Pages 315-323

  Sredniawa, Beata ^a   Mazurek, Michal ^a   Lenarczyk, Radoslaw ^a   Kowalski, Oskar ^a   Kowalczyk, Jacek ^a   Kalarus, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Heart failure; ICD; Implantable cardioverterdefibrillator; Myocardial infarction; Sudden cardiac death

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DEFIBRILLATOR; FOLLOW UP; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; SUDDEN DEATH;

DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 77952481609     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.15     Document Type: Review

References (39)

1. Ezekowitz JA, Rowe BH, Dryden DM et al.: Systematic review: implantable cardioverterdefibrillators for adults with left ventricular systolic dysfunction. Ann. Intern. Med. 147 (4), 251-262 (2007).
2. Zipes DP, Camm AJ, Borggrefe M et al.; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society: ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8 (9), 746-837 (2006).
3. Epstein AE, DiMarco JP, Ellenbogen KA et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons: ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA /NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 51 (21), E1-E62 (2008).
4. Moss AJ, Zareba W, Hall WJ et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346 (12), 877-883 (2002).
5. Wilber DJ, Zareba W, Hall WJ et al.: Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 109 (9), 1082-1084 (2004).
6. Bardy GH, Lee KL, Mark DB et al.: Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N. Engl. J. Med. 352 (3), 225-237 (2005).
7. Lim HS, Lip GY, Tse HF: Implantable cardioverter-defibrillator following acute myocardial infarction: the '48-hour' and '40-day' rule. Europace 10 (5), 536-539 (2008).
8. Huikuri HV, Castellanos A, Myerburg RJ: Sudden death due to cardiac arrhythmias. N. Engl. J. Med. 345 (20), 1473-1482 (2001).
9. Adabag AS, Therneau TM, Gersh BJ, Weston SA, Roger VL: Sudden death after myocardial infarction. JAMA 300 (17), 2022-2029 (2008).
10. Solomon SD, Zelenkofske S, McMurray JJ et al.: Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N. Engl. J. Med. 352 (25), 2581-2588 (2005). A study indicating the highest mortality rates of sudden cardiac death and cardiac arrest in the first 30 days after index infarction.
11. Hohnloser SH, Kuck KH, Dorian P et al.: Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N. Engl. J. Med. 351 (24), 2481-2488 (2004). First trial (Defibrillator in Acute Myocardial Infarction [DINAMIT]) that showed no reduction of total mortality in patients treated with implantable cardioverter-defibrillator (ICD) therapy in the early phase of myocardial infarction (MI).
12. Steinbeck G, Andresen D, Seidl K et al.: Defibrillator implantation early after myocardial infarction. N. Engl. J. Med. 361 (15), 1427-1436 (2009). Confirmatory (Immediate Risk Stratification Improves Survival [IRIS]) trial to DINAMIT that confirmed the lack of benefit from ICD therapy early after acute MI.
13. Garber AM, Hlatky MA: The confirmatory trial in comparative-effectiveness research. N. Engl. J. Med. 361 (15), 1498-1499 (2009).
14. Raviele A, Bongiorni MG, Brignole M et al.: Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal β-blocker treatment. The β-Blocker Strategy plus ICD Trial. Europace 7 (4), 327-337 (2005).
15. Zaman S, Sivagangabalan G, Narayan A, Thiagalingam A, Ross DL, Kovoor P: Outcomes of early risk stratification and targeted implantable cardioverter-defibrillator implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Circulation 120 (3), 194-200 (2009).
16. Moss AJ, Greenberg H, Case RB et al.: Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 110 (25), 3760-3765 (2004). Subanalysis of the MADIT-II trial, which showed a threefold increase in total mortality in patients with an ICD who experienced shock therapies due to ventricular arrhythmias.
17. Daubert JP, Zareba W, Cannom DS et al.: Inappropriate implantable cardioverterdefibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J. Am. Coll. Cardiol. 51 (14), 1357-1365 (2008).
18. Gatzoulis KA, Andrikopoulos GK, Apostolopoulos T et al.: Electrical storm is an independent predictor of adverse long-term outcome in the era of implantable defibrillator therapy. Europace 7 (2), 184-192 (2005).
19. Antman EM, Braunwald E: ST-elevation myocardial infarction: pathology, pathophysiology, and clinical features. In: Braunwald's Heart Disease: A textbook of Cardiovascular Medicine (8th Edition). Bonow L, Zipes M (Eds). Saunders Elsevier, PA, USA 1207-1232 (2008).
20. Auricchio A, Stellbrink C, Block M et al.: Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation 99 (23), 2993-3001 (1999).
21. Packer DL, Prutkin JM, Hellkamp AS et al.: Impact of implantable cardioverterdefibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 120 (22), 2170-2176 (2009).
22. Veltmann C, Borggrefe M, Schimpf R, Wolpert C: Fatal inappropriate ICD shock. J. Cardiovasc. Electrophysiol. 18 (3), 326-328 (2007).
23. Vollmann D, Ludie;thje L, Vonhof S, Unterberg C: Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm 2 (3), 307-309 (2005).
24. Tokano T, Bach D, Chang J et al.: Effect of ventricular shock strength on cardiac hemodynamics. J. Cardiovasc. Electrophysiol. 9 (8), 791-797 (1998).
25. Steinbeck G, Dorwarth U, Mattke S et al.: Hemodynamic deterioration during ICD implant: predictors of high-risk patients. Am. Heart J. 127 (4 part 2) 1064-1067 (1994).
26. Birk AV, Leno E, Robertson HD, Bolotina VM, Szeto HH: Interaction between ATP and catecholamines in stimulation of platelet aggregation. Am. J. Physiol. Heart Circ. Physiol. 284 (2), H619-H625 (2003).
27. Poole JE, Johnson GW, Hellkamp AS et al.: Prognostic importance of defibrillator shocks in patients with heart failure. N. Engl. J. Med. 359 (10), 1009-1017 (2008).
28. Wathen MS, DeGroot PJ, Sweeney MO et al.: Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 110 (17), 2591-2596 (2004). First trial (Pacing Fast VT Reduces Shock Therapies [PainFREE]) demonstrating that optimized ICD programming by increasing detection of the fast ventricular tachycardia zone up to 250 bpm with one sequence of antitachycardia pacing is efficient and safe and reduces the incidence of both appropriate and inappropriate shocks.
29. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM: A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J. Am. Coll. Cardiol. 48 (2), 330-339 (2006).
30. Wilkoff BL, Williamson BD, Stern RS et al.: Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J. Am. Coll. Cardiol. 52 (7), 541-550 (2008). Optimized ICD programming (strategically chosen ventricular tachycardia/ventricular fibrillation detection and therapy parameters) reduces adequate, inappropriate shocks and morbidity without undermining effective ICD therapy and without an increase in adverse events.
31. Gasparini M, Menozzi C, Proclemer A et al.: A simplifed biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter-defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of Long Detection Window Programming in Patients with Left Ventricular Dysfunction, Non-Ischemic Etiology in Primary Prevention Treated With a Biventricular ICD] study. Eur. Heart J. 30 (22), 2758-2767 (2009).
32. Nanthakumar K, Paquette M, Newman D et al.: Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter-defibrillators. Am. Heart J. 139 (5), 797-803 (2000).
33. Kudie;hlkamp V, Dodie;rnberger V, Mewis C, Suchalla R, Bosch RF, Seipel L: Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J. Cardiovasc. Electrophysiol. 10 (7), 905-915 (1999).
34. Deisenhofer I, Kolb C, Ndrepepa G et al.: Do current dual chamber cardioverterdefibrillators have advantages over conventional single chamber cardioverterdefibrillators in reducing inappropriate therapies? A randomized, prospective study. J. Cardiovasc. Electrophysiol. 12 (2), 134-142 (2001).
35. Friedman PA, McClelland RL, Bamlet WR et al.: Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation 113 (25), 2871-1879 (2006).
36. Theuns DA, Rivero-Ayerza M, Boersma E, Jordaens L: Prevention of inappropriate therapy in implantable defibrillators: a meta-ana lysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms. Int. J. Cardiol. 125 (3), 352-357 (2008).
37. Auricchio A, Stellbrink C, Sack S et al.: Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J. Am. Coll. Cardiol. 39 (12), 2026-2033 (2002). (Pubitemid 34628286)
38. Cazeau S, Leclercq C, Lavergne T et al.: Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N. Engl. J. Med. 344 (12), 873-880 (2001).
39. Costantini O, Hohnloser SH, Kirk MM et al.: The ABCD (Alternans Before Cardioverter-Defibrillator) trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J. Am. Coll. Cardiol. 53 (6), 471-479 (2009).